Altimmune announces initiation of 48-week phase 2 momentum trial of pemvidutide in obesity

The company also announces completion of enrollment in 12-week, phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (nafld) the company also announces completion of enrollment in 12-week, phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (nafld)
ALT Ratings Summary
ALT Quant Ranking